Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 1 trial of A4250 in children with PFIC types 1 and 2
NL-OMON48541Phase 3Active, not recruiting
- Sponsor
- Albireo Pharma
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of odevixibat in progressive familial intrahepatic cholestasis type 1 (PFIC1) and progressive familial intrahepatic cholestasis type 2 (PFIC2) (3 arms), sponsored by Albireo Pharma. Primary endpoints: Serum bile acid responder rate (EU and rest of world) and Positive pruritus assessments at subject level (US). Started Sep 2018; status: active, not recruiting.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis type 1 (PFIC1)progressive familial intrahepatic cholestasis type 2 (PFIC2)
Beyond the preview
Go deeper on NL-OMON48541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48541.